24/7 Customer Support

Press Release

Cancer Pain Diagnostics Market Revenue to Attain USD 11.23 Bn by 2033

8 January 2025

The global cancer pain diagnostics market revenue surpassed US$ 7.49 billion in 2024 and is predicted to attain around US$ 11.23 billion by 2033, growing at a CAGR of 4.6% during the forecast period from 2025 to 2033. The cancer pain diagnostics market is ready for robust expansion, driven by innovative technologies and a growing need for tailored care.

With a surge in investments and broader global accessibility, this sector is expected to transform pain management and greatly enhance patient outcomes. Key techniques in the cancer pain diagnostics field include imaging methods like MRI and CT scans, which are used in millions of procedures each year for evaluating pain.

ck_editor_img

Global Cancer Pain Diagnostics Market Key Takeaways

  • The cancer pain diagnostics market is projected to hit a market valuation of US$ 11.23 billion by 2033 at a CAGR of 4.6% during the forecast period 2025–2033.
  • While Europe lags behind North America, it maintains a significant presence in the cancer pain diagnostics market, thanks to its well-established healthcare systems and a proactive stance on cancer management.
  • In terms of drug utilization, opioids and narcotics are the primary choices in the cancer pain diagnostics market, owing to their effectiveness in relieving severe pain, which is a prevalent symptom for cancer patients. In 2023, this segment accounted for over 75% of the market share.
  • When examining disease indications, the demand for pain diagnostics is notably led by breast cancer, which surpasses other indications by securing more than 16% of the market share.

North America Stands as the Dominant Force in the Cancer Pain Diagnostics Market

North America emerges as the leading player in the cancer pain diagnostics market, capturing a substantial 42% share. This dominance is attributed to a combination of factors including an advanced healthcare infrastructure, significant healthcare expenditure, and a high incidence of cancer cases.

In 2024, it is projected that approximately 2.0 million individuals will receive a cancer diagnosis in the United States. Among these cases, an estimated 310,720 women and 2,790 men will be diagnosed with breast cancer, making it the most frequently diagnosed cancer in the country. Furthermore, prostate cancer tops the list for male diagnoses and ranks as the second most common cancer diagnosis overall, with 299,010 expected cases. Lung and bronchus cancer follows as the third most prevalent cancer, with an estimated 234,580 new cases.

In North America, the United States stands out for its healthcare spending, allocating significantly more per capita compared to other countries in the region. The majority of these healthcare costs are met through private insurance and out-of-pocket payments, contributing to a high overall healthcare expenditure relative to the nation’s Gross Domestic Product (GDP). In 2023, U.S. healthcare spending increased by 7.5%, reaching an impressive $4.9 trillion, which translates to about $14,570 per person. This expenditure accounted for 17.6% of the nation’s GDP, underscoring the country's significant financial commitment to healthcare.

Market Overview

Pain is one of the most prevalent symptoms experienced by cancer patients. It can arise from multiple sources, including cancer, various treatment modalities, or a combination of factors. Specific causes of pain may include tumors, surgery, intravenous chemotherapy, radiation therapy, targeted therapy, bisphosphonates, and even certain diagnostic procedures.

Interestingly, younger patients tend to experience cancer pain, and pain flares more frequently than their older counterparts. Additionally, those with advanced cancer report more severe pain levels, and many cancer survivors continue to experience pain even after their treatment has concluded.

Recent advancements in technology have introduced innovative solutions for pain assessment, notably through the integration of artificial intelligence and machine learning. These technologies enhance the precision of pain evaluations, allowing for more tailored treatment approaches. Furthermore, the adoption of wearable technology and remote monitoring systems is on the rise, with projections indicating that over 2 million devices will be in use by 2025. These developments promise to improve real-time diagnostics and the overall management of pain in cancer patients.

Global Cancer Pain Diagnostics Market Growth Factors

  • Integration of Digital Technology: The combination of digital technology with traditional diagnostic methodologies is enhancing precision in cancer pain assessments.
  • Personalized Medicine: There is a growing demand for personalized medicine specifically tailored to individual patient pain profiles, ensuring more effective management strategies.
  • Focus on Early Detection: An increased emphasis on early detection is being prioritized to improve patient outcomes and survival rates.
  • AI and Machine Learning Adoption: The use of artificial intelligence and machine learning is becoming more prevalent for predictive pain management analytics, allowing for proactive treatment adjustments.
  • Minimally Invasive Techniques: A shift towards minimally invasive diagnostic techniques is being embraced to enhance patient comfort while maintaining accuracy in assessments.
  • Expansion of Telemedicine: The growth of telemedicine platforms is facilitating remote cancer pain assessment and management, providing greater access to care for patients.

Market Dynamics

Driver

Rising Incidence of Cancer

The global cancer pain diagnostics market is experiencing significant growth, driven by the rising incidence of cancer worldwide. Each year, over 19 million new cancer cases are reported globally, highlighting the urgent need for effective pain management strategies.

Among the various types of cancer, lung cancer is the most common, affecting approximately 2.2 million individuals across the globe. This prevalence underscores the critical need for advanced diagnostics and treatment options to manage pain associated with this disease.

Geographically, countries such as the United States, China, India, and Brazil are notably impacted by cancer, with these nations collectively diagnosing over 5 million new cases annually. This significant number emphasizes the increasing demand for effective cancer pain diagnostics in regions with high cancer prevalence.

As the global population continues to age, the demand for cancer pain diagnostics is expected to rise. Currently, around 703 million people are aged 65 and older, a demographic that is more vulnerable to developing cancer and experiencing associated pain. This trend further drives the need for innovative pain management solutions within the cancer pain diagnostics market.

Restraint

Complexity in Standardizing Pain Assessment

Standardizing pain assessment within the realm of cancer diagnostics presents a considerable challenge due to the diverse demographics of patients in the cancer pain diagnostics market. The experience of cancer pain is influenced by a variety of factors, including age, gender, ethnicity, and cultural background, which complicates the feasibility of a one-size-fits-all approach.

The complexity of standardizing pain assessment is further underscored by the varied characteristics of the population affected by cancer pain. Notably, gender differences in pain perception have been observed, with studies showing that women often report higher pain severity yet tend to receive less aggressive pain management compared to their male counterparts.

These disparities highlight the urgent need for the development of more inclusive and representative assessment tools that take into account these demographic variations. By addressing these differences, the cancer pain diagnostics market can improve pain management strategies and enhance patient care outcomes.

Opportunity

Technological Advancements

The cancer pain diagnostics market is currently experiencing a rapid influx of technological advancements aimed at improving both diagnostic accuracy and patient comfort. Notably, the emergence of next-generation sequencing technologies has revolutionized pain diagnostics, with more than 1,000 genomic tests now available to identify pain-related biomarkers.

In addition, the integration of artificial intelligence into diagnostic processes has resulted in the development of over 150 AI-driven pain assessment tools. These tools facilitate faster and more accurate evaluations, enhancing the overall diagnostic experience for patients.

The landscape of cancer pain diagnostics is also seeing a significant increase in investment, with over 500 startups entering the field in the past two years. This surge in new companies highlights the lucrative opportunities available for stakeholders in the cancer pain diagnostics market, promising advancements that could benefit patients and healthcare providers alike.

Key Developments

  • In November 2024, Alverno Laboratories, one of the largest integrated laboratory networks in the United States, announced a partnership with Ibex Medical Analytics, the leader in AI-powered cancer diagnostics. Together, they launched the Ibex Breast platform for routine practice within Alverno’s laboratory network in Illinois and Indiana.
  • In October 2024, the National Institutes of Health (NIH) initiated research on non-opioid pain relief for oral cancer patients. This initiative received nearly $600,000 in grant funding from the NIH's National Institute of Dental and Craniofacial Research to tackle this critical issue that significantly affects patients' quality of life.
  • In July 2024, a new drug designed to control pain related to cancer treatment, originally developed at Stony Brook University, received FDA clearance. This development represents a significant advancement in pain management strategies for cancer patients.

Top Players in Cancer Pian Diagnostics Market

  • Aoxing Pharmaceutical Company, Inc.
  • BioDelivery Sciences International, Inc.
  • CK Life Sciences (WEX Pharmaceuticals)
  • Daiichi Sankyo Co., Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Mundipharma International Limited
  • Orexo AB
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Roche Holding AG
  • Other Prominent Players

Market Segmentation Overview

By Drug Type

  • Opioids/Narcotics
  • Morphine
  • Fentanyl
  • Others
  • Non-Opioids
  • Acetaminophen
  • Non-steroidal anti-inflammatory Drugs (NSAIDs)
  • Nerve Blocks

By Disease Indication

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

By Geography

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa (MEA)

For orders or any inquiries, feel free to contact us at [email protected] | +1 888 429 6757